FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395834915> ?p ?o ?g. }

• W2395834915 abstract "Tumor cells have an increased dependence on FASN-synthesized palmitate compared to non-tumor cells, which obtain many of their required lipids from the extracellular milieu. Palmitate and palmitate-derived lipids comprise diverse cellular components and function in processes required for tumor cell proliferation and survival. Previously we showed that FASN inhibition results in tumor cell apoptosis in vitro and xenograft tumor growth inhibition in vivo. Our studies demonstrated that diverse tumor types exhibit sensitivity to FASN inhibition and characterized mechanisms of action that associate with the antitumor activity of highly selective small molecule FASN inhibitors. In vitro studies with diverse tumor cell types elucidated a mechanism of action that includes plasma membrane remodeling, signal transduction pathway inhibition, and gene expression reprogramming. TVB-2640 and TVB-3166 belong to a series of orally available, reversible, potent, and selective FASN inhibitors discovered and developed by 3-V Biosciences. Tumor xenograft studies were conducted in rats and mice to examine the in vitro and in vivo relationship of tumor cell sensitivity to FASN inhibition. Pharmacodynamic analyses of tumor and serum samples from these studies characterized the mechanism of action and biomarkers of sensitivity to in vivo FASN inhibition. Once daily oral dosing of TVB-2640 or TVB-3166 caused inhibition of xenograft tumor growth for varied tumor models that included COLO-205 and HCT-116 colon adenocarcinoma cell lines. In vivo sensitivity to FASN inhibition was in agreement with in vitro data. Analysis of lipid, metabolite, protein, and RNA expression in tumor, blood or serum samples showed drug-induced modulation that was consistent with independent in vitro or in vivo studies. Lipid and metabolite changes included decreased palmitate and palmitate-associated lipids as well as increased expression of acylcarnitine species. Decreased expression of pAkt (S473), β-catenin, pβ-catenin (S675), and Myc proteins were found to associate quantitatively with xenograft tumor growth inhibition. Additionally, mRNA expression was modulated in a manner that revealed coordinated changes in the mRNAs from fatty acid, metabolism, cell survival, and cell growth-associated pathways. Expression changes in lipids, metabolites, proteins, and RNA species are leading to the development of a biomarker panel that describes FASN inhibitor target engagement and tumor sensitivity in both in vitro and in vivo studies. These mechanism-based marker panels will be evaluated in current and upcoming clinical studies of TVB-2640. Citation Format: Timothy S. Heuer, Richard Ventura, Kasia Mordec, Julie Lai, Joanna Waszczuk, Claudia Rubio, Marie O9 Farrell, Douglas Buckley, George Kemble. FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C175." @default.
• W2395834915 created "2016-06-24" @default.
• W2395834915 creator A5006394065 @default.
• W2395834915 creator A5020414960 @default.
• W2395834915 creator A5023527864 @default.
• W2395834915 creator A5025154671 @default.
• W2395834915 creator A5045051767 @default.
• W2395834915 creator A5061968298 @default.
• W2395834915 creator A5063172780 @default.
• W2395834915 creator A5084919600 @default.
• W2395834915 creator A5086374199 @default.
• W2395834915 date "2015-12-01" @default.
• W2395834915 modified "2023-09-27" @default.
• W2395834915 title "Abstract C175: FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640" @default.
• W2395834915 doi "https://doi.org/10.1158/1535-7163.targ-15-c175" @default.
• W2395834915 hasPublicationYear "2015" @default.
• W2395834915 type Work @default.
• W2395834915 sameAs 2395834915 @default.
• W2395834915 citedByCount "0" @default.
• W2395834915 crossrefType "proceedings-article" @default.
• W2395834915 hasAuthorship W2395834915A5006394065 @default.
• W2395834915 hasAuthorship W2395834915A5020414960 @default.
• W2395834915 hasAuthorship W2395834915A5023527864 @default.
• W2395834915 hasAuthorship W2395834915A5025154671 @default.
• W2395834915 hasAuthorship W2395834915A5045051767 @default.
• W2395834915 hasAuthorship W2395834915A5061968298 @default.
• W2395834915 hasAuthorship W2395834915A5063172780 @default.
• W2395834915 hasAuthorship W2395834915A5084919600 @default.
• W2395834915 hasAuthorship W2395834915A5086374199 @default.
• W2395834915 hasConcept C150903083 @default.
• W2395834915 hasConcept C185592680 @default.
• W2395834915 hasConcept C190283241 @default.
• W2395834915 hasConcept C202751555 @default.
• W2395834915 hasConcept C207001950 @default.
• W2395834915 hasConcept C502942594 @default.
• W2395834915 hasConcept C55493867 @default.
• W2395834915 hasConcept C62112901 @default.
• W2395834915 hasConcept C86803240 @default.
• W2395834915 hasConcept C98274493 @default.
• W2395834915 hasConceptScore W2395834915C150903083 @default.
• W2395834915 hasConceptScore W2395834915C185592680 @default.
• W2395834915 hasConceptScore W2395834915C190283241 @default.
• W2395834915 hasConceptScore W2395834915C202751555 @default.
• W2395834915 hasConceptScore W2395834915C207001950 @default.
• W2395834915 hasConceptScore W2395834915C502942594 @default.
• W2395834915 hasConceptScore W2395834915C55493867 @default.
• W2395834915 hasConceptScore W2395834915C62112901 @default.
• W2395834915 hasConceptScore W2395834915C86803240 @default.
• W2395834915 hasConceptScore W2395834915C98274493 @default.
• W2395834915 hasLocation W23958349151 @default.
• W2395834915 hasOpenAccess W2395834915 @default.
• W2395834915 hasPrimaryLocation W23958349151 @default.
• W2395834915 hasRelatedWork W1935967979 @default.
• W2395834915 hasRelatedWork W2017348588 @default.
• W2395834915 hasRelatedWork W2027320585 @default.
• W2395834915 hasRelatedWork W2031414168 @default.
• W2395834915 hasRelatedWork W2042605361 @default.
• W2395834915 hasRelatedWork W2051701264 @default.
• W2395834915 hasRelatedWork W2072294095 @default.
• W2395834915 hasRelatedWork W2295755787 @default.
• W2395834915 hasRelatedWork W2333055015 @default.
• W2395834915 hasRelatedWork W2506429361 @default.
• W2395834915 hasRelatedWork W2567412474 @default.
• W2395834915 hasRelatedWork W2592408028 @default.
• W2395834915 hasRelatedWork W2913768185 @default.
• W2395834915 hasRelatedWork W2980583862 @default.
• W2395834915 hasRelatedWork W3000024409 @default.
• W2395834915 hasRelatedWork W3045830102 @default.
• W2395834915 hasRelatedWork W3048795921 @default.
• W2395834915 hasRelatedWork W3099236 @default.
• W2395834915 hasRelatedWork W3202805077 @default.
• W2395834915 hasRelatedWork W3206191919 @default.
• W2395834915 isParatext "false" @default.
• W2395834915 isRetracted "false" @default.
• W2395834915 magId "2395834915" @default.
• W2395834915 workType "article" @default.